Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Language
Publication year range
1.
Ann Vasc Surg ; 74: 450-459, 2021 Jul.
Article in English | MEDLINE | ID: mdl-33556506

ABSTRACT

BACKGROUND-OBJECTIVE: Prior studies have suggested a higher prevalence of simple renal cysts (SRC) among patients with aortic disease, including abdominal aortic aneurysms (AAA). Thus, the aim of this study was to systematically review all currently available literature and investigate whether patients with AAA are more likely to have SRC. METHODS: This study was performed according to the PRISMA guidelines. A meta-analysis was conducted with the use of random effects modeling and the I-square was used to assess heterogeneity. Odds ratios (OR) and the corresponding 95% confidence intervals (CI) were synthesized to compare the prevalence of several patients' characteristics between AAA vs. no-AAA cases. RESULTS: Eleven retrospective studies, 9 comparative (AAA vs. no-AAA groups) and 3 single-arm (AAA group), were included in this meta-analysis, enrolling patients (AAA: N = 2,297 vs. no-AAA: N = 35,873) who underwent computed tomography angiography as part of screening or preoperative evaluation for reasons other than AAA. The cumulative incidence of SRC among patients with AAA and no-AAA was 55% (95% CI: 49%-61%) and 32% (95% CI: 22%-42%) respectively, with a statistically higher odds of SRC among patients with AAA (OR: 3.02; 95% CI: 2.01-4.56; P< 0.001). The difference in SRC prevalence remained statistically significant in a sensitivity analysis, after excluding the study with the largest sample size (OR: 2.71; 95% CI: 1.91-3.84; P< 0.001). CONCLUSIONS: Our meta-analysis demonstrated a 3-fold increased prevalence of SRC in patients with AAA compared to no-AAA cases, indicating that the pathogenic processes underlying SRC and AAA could share a common pathophysiologic mechanism. Thus, patients with SRC could be considered at high risk for AAA formation, potentially warranting an earlier AAA screening.


Subject(s)
Aortic Aneurysm, Abdominal/complications , Kidney Diseases, Cystic/complications , Comorbidity , Confidence Intervals , Dyslipidemias/complications , Female , Humans , Kidney Diseases, Cystic/epidemiology , Male , Odds Ratio , Prevalence
2.
J Am Heart Assoc ; 6(7)2017 07 15.
Article in English | MEDLINE | ID: mdl-28711864

ABSTRACT

BACKGROUND: The relative benefit of higher statin dosing in patients with peripheral artery disease has not been reported previously. We compared the effectiveness of low- or moderate-intensity (LMI) versus high-intensity (HI) statin dose on clinical outcomes in patients with peripheral artery disease. METHODS AND RESULTS: We reviewed patients with symptomatic peripheral artery disease who underwent peripheral angiography and/or endovascular intervention from 2006 to 2013 who were not taking other lipid-lowering medications. HI statin use was defined as atorvastatin 40-80 mg or rosuvastatin 20-40 mg. Baseline demographics, procedural data, and outcomes were retrospectively analyzed. Among 909 patients, 629 (69%) were prescribed statins, and 124 (13.6%) were treated with HI statin therapy. Mean low-density lipoprotein level was similar in patients on LMI versus HI (80±30 versus 87±44 mg/dL, P=0.14). Demographics including age (68±12 versus 67±10 years, P=0.25), smoking history (76% versus 80%, P=0.42), diabetes mellitus (54% versus 48%, P=0.17), and hypertension (88% versus 89%, P=0.78) were similar between groups (LMI versus HI). There was a higher prevalence of coronary artery disease (56% versus 75%, P=0.0001) among patients on HI statin (versus LMI). After propensity weighting, HI statin therapy was associated with improved survival (hazard ratio for mortality: 0.52; 95% confidence interval, 0.33-0.81; P=0.004) and decreased major adverse cardiovascular events (hazard ratio: 0.58; 95% confidence interval 0.37-0.92, P=0.02). CONCLUSIONS: In patients with peripheral artery disease who were referred for peripheral angiography or endovascular intervention, HI statin therapy was associated with improved survival and fewer major adverse cardiovascular events compared with LMI statin therapy.


Subject(s)
Atorvastatin/administration & dosage , Dyslipidemias/drug therapy , Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage , Intermittent Claudication/drug therapy , Ischemia/drug therapy , Peripheral Arterial Disease/drug therapy , Rosuvastatin Calcium/administration & dosage , Aged , Aged, 80 and over , Amputation, Surgical , Angiography , Atorvastatin/adverse effects , Biomarkers/blood , Critical Illness , Disease Progression , Disease-Free Survival , Drug Prescriptions , Dyslipidemias/blood , Dyslipidemias/diagnostic imaging , Dyslipidemias/mortality , Endovascular Procedures , Female , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects , Intermittent Claudication/blood , Intermittent Claudication/diagnostic imaging , Intermittent Claudication/mortality , Ischemia/blood , Ischemia/diagnostic imaging , Ischemia/mortality , Kaplan-Meier Estimate , Lipids/blood , Male , Middle Aged , Peripheral Arterial Disease/blood , Peripheral Arterial Disease/diagnostic imaging , Peripheral Arterial Disease/mortality , Practice Patterns, Physicians'/trends , Registries , Retrospective Studies , Risk Factors , Rosuvastatin Calcium/adverse effects , Time Factors , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL